Eradivir Funding & Investors

West Lafayette, IN

Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19.

Total Amount Raised: $11,056,000

Eradivir Funding Rounds

Series A
$9,800,000
Sep 22, 2024
Series A Investors
Philip S. Low
Grant
$1,000,000
Sep 22, 2024
Grant Investors
National Science Foundation (NSF)
Biomedical Advanced Research and Development Authority (BARDA)
Grant
$256,000
Feb 4, 2021
Grant Investors
National Science Foundation (NSF)

Funding info provided by Diffbot.